Disclosed herein are compounds of formula (I), and pharmaceutical compositions comprising the same. The compounds of formula (I) are neutrophilic inflammation inhibitors, thus, they are useful for treatment and/or prophylaxis of inflammatory diseases and/or disorders associated with abnormal activation of neutrophils, such as ARDS, ALI, COPD, lung fibrosis, chronic bronchitis, pulmonary emphysema, α-1 anti-trypsin deficiency, cystic fibrosis, idiopathic pulmonary fibrosis, liver injury, steatohepatitis, liver fibrosis, damages caused by ischemia and reperfusion, myocardial infarction, shock, stroke, and organ transplantation, ulcerative cholitis, vasculitis, SLE, sepsis, SIRS, arthritis, psoriasis, atopic dermatitis, and inflammatory skin diseases.在此揭示式(I)化合物以及包含此式(I)化合物的藥學組合物。所揭示的式(I)化合物為嗜中性白血球發炎抑制劑，因此可用於治療和/或預防發炎疾病和/或與嗜中性白血球異常活化相關的疾病，例如成人呼吸窘迫症候群(Adult respiratory distress syndrome, ARDS)、急性肺損傷(acute lung injury, ALI)、慢性肺阻塞(chronic obstructive pulmonary disease, COPD)、肺纖維化、慢性支氣管炎、肺氣腫、α-1抗胰蛋白酶缺乏症、囊狀纖維化、隱源性纖維化肺泡炎、肝臟損傷、脂肪性肝炎、肝纖維化、因缺血及再灌流所引發的損傷、心肌梗塞、休克、中風、器官移植、潰瘍性結腸炎、血管炎、全身性紅斑狼瘡(systemic lupus erythematosus, SLE)、敗血症、全身性炎症反應症候群(systemic inflammatory response syndrome, SIRS)、牛皮癬、異位性皮膚炎、及發炎性皮膚病。
